Afelimomab Explained

Afelimomab (MAK 195F) is an anti-TNFα monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.^{[1] [2]}

Notes and References

1. Rondon E, Venkataraman R . Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels . Critical Care . 9 . 5 . E20 . August 2005 . 16277704 . 1297624 . 10.1186/cc3798 . free .
2. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, Teoh L, Van Meter L, Daum L, Lemeshow S, Hicklin G, Doig C . 6 . Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels . Critical Care Medicine . 32 . 11 . 2173–82 . November 2004 . 15640628 . 10.1097/01.CCM.0000145229.59014.6C . Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators . 23321488 .